KRAS and prostate carcinoma: MiRNA-30 c could suppress prostate cancer survival by targeting KRAS Proto-Oncogene [23], E2F Transcription Factor 7 (E2F7) [8], or alternative splicing factor/splicing factor 2 (ASF/SF2) [24].